Deferred Tax Assets, Valuation Allowance of KalVista Pharmaceuticals, Inc. from 31 Dec 2013 to 30 Apr 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
KalVista Pharmaceuticals, Inc. quarterly Deferred Tax Assets, Valuation Allowance in USD history and change rate from 31 Dec 2013 to 30 Apr 2025.
  • KalVista Pharmaceuticals, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending 30 Apr 2025 was $65,064,000, a 11% increase year-over-year.
Source SEC data
View on sec.gov
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Change (%)

KalVista Pharmaceuticals, Inc. Quarterly Deferred Tax Assets, Valuation Allowance (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q1 2025 $65,064,000 +$6,527,000 +11% 30 Apr 2025 10-K 10 Jul 2025 2025 FY
Q1 2024 $58,537,000 +$13,261,000 +29% 30 Apr 2024 10-K 10 Jul 2025 2025 FY
Q1 2023 $45,276,000 +$17,064,000 +60% 30 Apr 2023 10-K 11 Jul 2024 2024 FY
Q1 2022 $28,212,000 +$11,182,000 +66% 30 Apr 2022 10-K 10 Jul 2023 2023 FY
Q1 2021 $17,030,000 +$7,501,000 +79% 30 Apr 2021 10-K 07 Jul 2022 2022 FY
Q1 2020 $9,529,000 +$1,137,000 +14% 30 Apr 2020 10-K 13 Jul 2021 2021 FY
Q1 2019 $8,392,000 +$1,556,000 +23% 30 Apr 2019 10-K 01 Jul 2020 2020 FY
Q1 2018 $6,836,000 +$952,000 +16% 30 Apr 2018 10-K 16 Jul 2019 2019 FY
Q1 2017 $5,884,000 +$3,038,000 +107% 30 Apr 2017 10-K 30 Jul 2018 2018 FY
Q1 2016 $2,846,000 30 Apr 2016 10-K 27 Jul 2017 2017 FY
Q4 2015 $28,783,000 +$10,540,000 +58% 31 Dec 2015 10-K 30 Mar 2016 2015 FY
Q4 2014 $18,243,000 +$3,978,000 +28% 31 Dec 2014 10-K 30 Mar 2016 2015 FY
Q4 2013 $14,265,000 31 Dec 2013 10-K 30 Mar 2016 2015 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.